Form 4: Aclaris CFO Kevin Balthaser Receives Equity Awards

Aclaris Therapeutics' CFO, Kevin Balthaser, received significant equity awards, including restricted stock units and stock options, effective February 2, 2026.

Summary

• Kevin Balthaser, Chief Financial Officer of Aclaris Therapeutics, Inc., was granted 99,100 Restricted Stock Units (RSUs).
• The RSUs represent a contingent right to receive one share of common stock per unit.
• The shares underlying these RSUs will vest in four equal installments on the first, second, third, and fourth anniversaries of February 2, 2026, contingent on continuous service.
• Balthaser also received an Employee Stock Option to buy 346,800 shares of common stock at an exercise price of $3.61 per share.
• This stock option will vest with respect to 25% of the shares in four equal installments on the first, second, third, and fourth anniversaries of February 2, 2026, also subject to continuous service.
• The employee stock option has an expiration date of February 1, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the strong alignment of the CFO's long-term financial interests with those of the shareholders, which is a positive for corporate governance and executive retention.

Positives

• The equity awards align the Chief Financial Officer's interests with those of shareholders, incentivizing long-term performance.
• The grants represent a significant component of executive compensation, reflecting confidence in the executive's continued contribution to the company.

Risks

• The value of the restricted stock units and stock options is subject to the future market price fluctuations of Aclaris Therapeutics' common stock.
• Vesting of both the RSUs and stock options is contingent upon Kevin Balthaser's continuous service to the company, meaning forfeiture if employment ceases before vesting dates.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend over four years from February 2, 2026, indicating a long-term incentive structure designed to retain the Chief Financial Officer and align his performance with the company's sustained success.

Industry Context

StockSavvy.ai notes that granting equity awards such as restricted stock units and stock options is a standard practice in the biotechnology and pharmaceutical industries for executive compensation. This approach is widely used to attract, retain, and motivate key personnel by linking their personal wealth directly to the company's stock performance and long-term value creation.

Comparison to Industry Standards

• The structure of these equity awards, with multi-year vesting schedules, is consistent with typical executive compensation packages observed across the biotech sector, including companies like Regeneron Pharmaceuticals and Biogen, which frequently use similar long-term incentives to foster executive retention and performance alignment.
• The specific amounts granted are within the expected range for a Chief Financial Officer at a company of Aclaris Therapeutics' size and stage, comparable to grants seen at peer companies in the small to mid-cap biopharma space.

Stakeholder Impact

• Shareholders: The equity awards are designed to align the Chief Financial Officer's incentives with shareholder value creation, potentially leading to improved long-term performance.
• Employees: The compensation structure for a key executive may influence overall compensation philosophy and morale within the company.
• Creditors: No direct impact on creditors from this specific filing.

Next Steps

• The vesting of the Restricted Stock Units and Employee Stock Options will occur in four equal annual installments starting February 2, 2027, subject to continuous service.

Key Dates

Recommendation

The filing details routine executive compensation through equity awards, which is a positive for management alignment and retention. However, a Form 4 alone does not provide sufficient information regarding the company's operational performance, financial health, or strategic direction to warrant a change in investment recommendation. It reinforces a 'hold' stance by indicating stable corporate governance practices regarding executive incentives.

Keywords

Aclaris Therapeutics, ACRS, Form 4, Insider Transaction, Equity Award, Restricted Stock Units, Stock Options, CFO Compensation, Executive Compensation